SABS

Sab Biotherapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 7/10
  • Momentum↑ 8/10
Sab Biotherapeutics sales and earnings growth
SABS Growth
Good
  • Revenue Y/Y↓ -92.42%
  • EPS Y/Y↑ 62.22%
  • FCF Y/Y↓ 2.52%
Sab Biotherapeutics gross and profit margin trends
SABS Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↑ 16338.30%
  • ROIC↑ 32.60%
Sab Biotherapeutics net debt vs free cash flow
SABS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 76.5

Sab Biotherapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗